Receptos to Deliver Scientific Presentations about RPC1063 at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
SAN DIEGO, Oct. 9, 2012 /PRNewswire/ -- Receptos Inc. today announced that company personnel will deliver two scientific poster presentations about RPC1063 at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting in Lyon, France, from October 10 to 13, 2012. For a quarter of a century, ECTRIMS has served as Europe's and the world's largest professional organization dedicated to the understanding and treatment of multiple sclerosis (MS). RPC1063 is the company's lead sphingosine 1-phosphate 1 receptor (S1P1) agonist in development for both MS and inflammatory bowel disease (IBD).
The first Receptos abstract, titled, "Safety and tolerability of orally administered RPC1063, a novel S1P1 receptor agonist, in healthy adult volunteers," discusses the assessment of RPC1063 in a single and multiple ascending daily dose Phase 1 clinical trial.
The second Receptos abstract, titled, "RPC1063, a potent, selective S1P1 receptor modulator, is active in a therapeutic EAE model and exhibits favorable PK/PD properties in healthy volunteers," characterizes the preclinical specificity, potency and efficacy, as well as the clinical pharmacokinetics (PK) and pharmacodynamics (PD) of RPC1063.
"The combined preclinical and Phase 1 clinical data relating to RPC1063 reveals a potential best-in-class profile in the S1P1 agonist class," said Faheem Hasnain, President and Chief Executive Officer of Receptos. "The acceptance of these scientific data presentations at ECTRIMS underscores the enthusiasm on the part of clinical investigators to explore the novel profile of RPC1063 in multiple sclerosis patients in upcoming efficacy trials."
About RPC1063 and S1P1 Modulators
RPC1063 is a novel, differentiated S1P1 selective modulator exhibiting picomolar potency that is effective in rodent models of both MS and IBD, and possesses an excellent safety profile in non-clinical toxicology studies. Receptos has completed a Phase 1 clinical safety study with RPC1063 under a US IND that supports the desired differentiation profile and establishes justification for initiation of MS and IBD clinical efficacy trials in 2012. S1P1 is a G protein-coupled receptor (GPCR) that binds the lipid signaling molecule sphingosine 1-phosphate (S1P). S1P is a circulating lipid that binds to five GPCRs termed S1P1-5. S1P1 selectively regulates physiological functions in the immune and cardiovascular systems, including immune cell trafficking and the maintenance of endothelial integrity. In autoimmune disorders, S1P1 agonism works by selectively sequestering circulating lymphocytes, blunting the underlying cause of disease.
Receptos is a biopharmaceutical company developing autoimmune therapeutic candidates through information - driven drug discovery, including GPCR structure determination. The company's lead program, RPC1063, is a potential best-in-class S1P1 small molecule modulator candidate for autoimmune indications. Patents supporting RPC1063 were exclusively licensed to Receptos from The Scripps Research Institute (TSRI). The discoveries originated in the NIH Molecular Libraries Probe Production Center at TSRI, which is part of the NIH Common Fund Molecular Libraries initiative (http://commonfund.nih.gov/molecularlibraries/). Receptos' expertise in S1P1 biology has been informed by the company's high resolution protein crystal structure of the S1P1 receptor, published in Science earlier this year. Receptos has established partnerships for its GPCR structure determination technology platform with Eli Lilly, Ono Pharmaceutical and Janssen Pharmaceuticals, Inc. For more information visit www.receptos.com.
SOURCE Receptos Inc.
Web Site: http://www.russopartnersllc.com
Posted: October 2012